BioMarin Pharmaceutical

BioMarin Pharmaceutical (nasdaq: BMRN) is a biotechnology firm based in Novato, California. It has offices and facilities both the US and Europe. BioMarin's core business and research is in enzyme replacement therapies. BioMarin is the first company provide therapeutics for mucopolysaccharidosis type I (MPS I), by manufacturing Aldurazyme® (commercialized by Genzyme Corporation).

As of 2005, BioMarin has commercialized Naglazyme™ (galsulfase)as an enzyme replacement therapy for the treatment of mucopolysaccharidosis VI (MPS VI).